Skip to content
10-Q

Quarterly Report

MERIDIAN BIOSCIENCE, INC.

0001193125-22-027781

← back to feed
Filed
Feb 4, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · Jan 31, 2022 43.54M sh
Long Term Debt Q1 2022 · Dec 31, 2021 $50M
Long Term Debt Q1 2022 · Sep 30, 2021 $60M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $72.73M
Cash And Equivalents Q1 2022 · Sep 30, 2021 $49.77M
Cash And Equivalents Q1 2022 · Dec 31, 2020 $63.19M
Cash And Equivalents Q1 2022 · Sep 30, 2020 $53.51M
Current Liabilities Q1 2022 · Dec 31, 2021 $49.95M
Current Liabilities Q1 2022 · Sep 30, 2021 $47.16M
Current Assets Q1 2022 · Dec 31, 2021 $203.65M
Current Assets Q1 2022 · Sep 30, 2021 $192.81M
Total Assets Q1 2022 · Dec 31, 2021 $458.64M
Total Assets Q1 2022 · Sep 30, 2021 $449.72M
Shares Diluted Q1 2022 · Dec 31, 2020 43.78M sh
Capex Q1 2022 · Dec 31, 2020 $2.09M
Operating Cash Flow Q1 2022 · Dec 31, 2020 $25.12M
Stockholders Equity Q1 2022 · Dec 31, 2020 $278.87M
Stockholders Equity Q1 2022 · Sep 30, 2020 $247.63M
Eps Diluted Q1 2022 · Dec 31, 2020 $0.61
Eps Basic Q1 2022 · Dec 31, 2020 $0.62
Sga Expense Q1 2022 · Dec 31, 2020 $11.94M
Rd Expense Q1 2022 · Dec 31, 2020 $5.65M
Net Income Q1 2022 · Dec 31, 2020 $26.78M
Operating Income Q1 2022 · Dec 31, 2020 $34.66M
Gross Profit Q1 2022 · Dec 31, 2020 $61.55M
Cost Of Revenue Q1 2022 · Dec 31, 2020 $31.37M
Revenue Q1 2022 · Dec 31, 2020 $92.92M